Clinical Trials Browser

Completed × Lung Neoplasms × Sorafenib × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

16 enrolled

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00454194 2017-03-21

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

110 enrolled 15 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00411671 2016-02-11

BATTLE Program: Sorafenib in Patients With NSCLC

Phase 2 Completed

105 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00533585 2016-02-10

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

23 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT00466232 2015-12-16

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

Phase 1 Completed

16 enrolled

Thoracic

Lung Neoplasms, Carcinoma, Small Cell

NCT00456716 2010-03-04

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Phase 2 Completed

5 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Clinical Trials

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

BATTLE Program: Sorafenib in Patients With NSCLC

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma